GLSI (Greenwich LifeSciences) Risk Assessment


GLSI Greenwich LifeSciences Inc GLSI
35 GF Score
Price $20.37
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Greenwich LifeSciences is: No Data: Cannot be evaluated.

Greenwich LifeSciences  (NAS:GLSI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Greenwich LifeSciences Risk Assessment Related Terms

GLSI vs SABS, SRZN, ZNTL: Risk Assessment Comparison

For the Biotechnology subindustry, Greenwich LifeSciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Greenwich LifeSciences Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Risk Assessment falls into.


GLSI
35GF Score
Greenwich LifeSciences Inc GLSI
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
35GF Score

Get the complete analysis for GLSI

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.37
Price